Anti-T cell strategies in asthma.
Chronic asthma is characterised by inflammation of the airways. Although corticosteroids are effective therapy, the risk benefit ratio is unacceptable in a minority of patients requiring chronic and high dose corticosteroid therapy because of adverse effects. There is accumulating circumstantial evidence that the CD4+ T-cell plays a central role in the pathogenesis of chronic asthma. Therapeutic strategies directed specifically at this cell type may offer a novel approach. Controlled clinical trials of cyclosporin A were effective in both chronic asthma and in a model of provoked asthma. Other immunomodulators such as FK506, rapamycin and mycophenolic acid may be useful given their modes of action on the T lymphocyte. The use of monoclonal antibody therapy directed towards these cells and T-cell peptide specific immunotherapy have been evaluated in preliminary studies and demonstrated promising results. Strategies targeting T cell co-stimulatory molecules and T-cell derived cytokines may be of therapeutic utility.
Kon
O M
OM
Department of Allergy and Clinical Immunology, National Heart and Lung Institute, Imperial College School of Medicine, London, UK.
Kay
A B
AB
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001249:Asthma / Q000209:etiology / Q000276:immunology / Q000628:therapy*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D006801:Humans; D007167:Immunotherapy
D000911:Antibodies, Monoclonal